Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn more about how the study drug, methadone, prescribed by an infant's or child's physician as part of standard medical care, is processed in children and young adults. While this drug is used extensively in infants and children, it has not been extensively studied in this population.

Physicians do not have very much information on how long it takes for methadone to be removed from the blood circulation and passed out of the body. Physicians need more information to guide how much and how often we should give methadone to children/young adults to ensure they get the maximum effect with the minimum amount of drug. During this research study, the study team will collect information about how this drug is processed in infants and children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of approximately 24 to 36 infants and children will participate in this study. This study will be done at five medical centers in the United States.

Treatment will be prescribed by the infant or child's doctor and not by the study team.

Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2 to 6 years, and ages 6 to 18 years. There will be approximately 8 to 12 participants enrolled in each group. Additionally, at least 6 overweight or obese participants between ages 2-18 years will be included in this study.

Information collected from each subject's routine medical care will include:

* Participant gender, date of birth, race and ethnicity
* Pertinent medical history
* Laboratory results (blood count and chemistries) from routine testing ordered by the infant or child's regular doctor
* Medications of interest the child was given within the 72 hours prior to first dose of methadone administered after consent
* Time and dose of methadone administered to the child up to 14 days prior to enrollment

Study specific information collected will include:

* Blood sample collection to measure level of methadone
* Baseline WAT-1 score (sedation withdrawal assessment of the infant or child used to assess symptoms the child/infant may experience when opioid drugs are discontinued).

The duration of the study will be up to 10 days, comprised of a maximum 5 day treatment period a 5 day observation period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opiate Withdrawal Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Opiate withdrawal in children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* \>90 days - \< 18 years of age at the time of first dose of study drug
* Receiving enteral methadone as standard of care
* Signed informed consent/HIPAA documents by the parent/legal guardian and assent (if applicable)

Exclusion Criteria

* Previous participation in the study
* Subject is receiving ECLS (Extracorporeal Life Support)
* \< 36 weeks gestational age at birth for children \<1 year of age at time of enrollment
* Any other condition or chronic illness that in the opinion of the Principal
* Investigator makes participation unadvised or unsafe

Minimum Eligible Age

91 Days

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kevin Watt

Assistant Professor of Pediatrics

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kevin watt, MD

Role: PRINCIPAL_INVESTIGATOR

Duke Medical Center/Duke Clinical Research Institute

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HHSN27500021

Identifier Type: OTHER

Identifier Source: secondary_id

Pro00044082

Identifier Type: -

Identifier Source: org_study_id

Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Cohort 1

Methadone

Cohort 2

Methadone

Cohort 3

Methadone

Interventions

Methadone

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Kevin Watt

Responsible Party

Kevin Watt

Principal Investigators

Kevin watt, MD

Locations

All Children's Hospital

Children's Mercy Hospital

C.S. Mott Children's Hospital

Duke University Medical Center

Medical University of South Carolina

Countries

Other Identifiers

HHSN27500021

Pro00044082